Your browser doesn't support javascript.
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
Ko, Meehyun; Jeon, Sangeun; Ryu, Wang-Shick; Kim, Seungtaek.
  • Ko M; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea.
  • Jeon S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea.
  • Ryu WS; CEO Office, Institut Pasteur Korea, Seongnam, Korea.
  • Kim S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea.
J Med Virol ; 93(3): 1403-1408, 2021 03.
Article in English | MEDLINE | ID: covidwho-1196439
ABSTRACT
Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / Guanidines Limits: Animals / Humans Country/Region as subject: North America Language: English Journal: J Med Virol Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / Guanidines Limits: Animals / Humans Country/Region as subject: North America Language: English Journal: J Med Virol Year: 2021 Document Type: Article